119 related articles for article (PubMed ID: 7524323)
1. The utility of fetal biometry as an adjunct to the multiple-marker screening test for Down syndrome.
Owen J; Wenstrom KD; Hardin JM; Boots LR; Hsu CC; Cosper PC; DuBard MB
Am J Obstet Gynecol; 1994 Oct; 171(4):1041-6. PubMed ID: 7524323
[TBL] [Abstract][Full Text] [Related]
2. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age.
Bahado-Singh RO; Oz AU; Kovanci E; Deren O; Copel J; Baumgarten A; Mahoney J
Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1627-31. PubMed ID: 9855608
[TBL] [Abstract][Full Text] [Related]
3. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
[TBL] [Abstract][Full Text] [Related]
4. Potential prenatal predictions of Down syndrome: a statistical analysis.
O'Brien WF; Knuppel RA; Torres C; Sternlicht D
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1796-8. PubMed ID: 1701614
[TBL] [Abstract][Full Text] [Related]
5. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers.
Nyberg DA; Luthy DA; Cheng EY; Sheley RC; Resta RG; Williams MA
Am J Obstet Gynecol; 1995 Oct; 173(4):1030-5. PubMed ID: 7485289
[TBL] [Abstract][Full Text] [Related]
6. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
7. The comprehensive midtrimester test: high-sensitivity Down syndrome test.
Bahado-Singh R; Shahabi S; Karaca M; Mahoney MJ; Cole L; Oz UA
Am J Obstet Gynecol; 2002 Apr; 186(4):803-8. PubMed ID: 11967511
[TBL] [Abstract][Full Text] [Related]
8. The effect of fetal gender on the prediction of Down syndrome by means of maternal serum alpha-fetoprotein and ultrasonographic parameters.
Lockwood CJ; Lynch L; Ghidini A; Lapinski R; Berkowitz G; Thayer B; Miller WA
Am J Obstet Gynecol; 1993 Nov; 169(5):1190-7. PubMed ID: 7694466
[TBL] [Abstract][Full Text] [Related]
9. Detection of fetal Turner syndrome with multiple-marker screening.
Wenstrom KD; Williamson RA; Grant SS
Am J Obstet Gynecol; 1994 Feb; 170(2):570-3. PubMed ID: 7509569
[TBL] [Abstract][Full Text] [Related]
10. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
11. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
Burton BK; Prins GS; Verp MS
Am J Obstet Gynecol; 1993 Sep; 169(3):526-30. PubMed ID: 7690522
[TBL] [Abstract][Full Text] [Related]
12. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome.
Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756
[TBL] [Abstract][Full Text] [Related]
13. Antenatal screening for Down's syndrome: where are we and where next?
Haddow JE
Lancet; 1998 Aug; 352(9125):336-7. PubMed ID: 9717914
[No Abstract] [Full Text] [Related]
14. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome.
Benn PA; Horne D; Briganti S; Greenstein RM
Am J Obstet Gynecol; 1995 Aug; 173(2):496-501. PubMed ID: 7544068
[TBL] [Abstract][Full Text] [Related]
15. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric inhibin A and ultrasound.
Debiève F; Bouckaert A; Hubinont C; Thomas K
Gynecol Obstet Invest; 2000; 49(4):221-6. PubMed ID: 10828702
[TBL] [Abstract][Full Text] [Related]
16. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results.
Bahado-Singh RO; Goldstein I; Uerpairojkit B; Copel JA; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1995 Oct; 173(4):1106-10. PubMed ID: 7485301
[TBL] [Abstract][Full Text] [Related]
17. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old.
Wenstrom KD; Desai R; Owen J; DuBard MB; Boots L
Am J Obstet Gynecol; 1995 Oct; 173(4):1287-92. PubMed ID: 7485339
[TBL] [Abstract][Full Text] [Related]
18. The influence of maternal weight on human chorionic gonadotropin in the multiple-marker screening test for fetal Down syndrome.
Wenstrom KD; Owen J; Boots L; Ethier M
Am J Obstet Gynecol; 1995 Oct; 173(4):1297-300. PubMed ID: 7485341
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein, free beta-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome.
Wenstrom KD; Owen J; Chu DC; Boots L
Am J Obstet Gynecol; 1997 Nov; 177(5):987-91. PubMed ID: 9396880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
